27.02.2013 • News • International Chemical Investors Group • International Chemical Investors Group (ICIG) • Corden Pharma

CordenPharma Expands with ICIG Acquisition of Farchemia

CordenPharma announces an expansion of manufacturing capabilities due to the recent acquisition by International Chemical Investors Group (ICIG) of Farchemia from the Tessenderlo Group, completed on December 5th, 2012.

Farchemia, located in Bergamo, Italy, brings to CordenPharma expanded capabilities in developing and manufacturing advanced intermediates and APIs for the pharmaceutical industry in all major markets. Farchemia's portfolio is comprised of cGMP custom synthesis from lab to multi-ton scale, multi-step API process development, contract manufacturing, and full suite of proprietary generic APIs. Farchemia employs approximately 150 people and generates nearly €50 million in annual sales.

Special Issue

Explore the Future of Plastics

Circular Plastics Economy

This special CHEManager issue explores the industry’s pivotal shift towards a more sustainable, circular plastics value chain. Readers will find expert analysis and real-world solutions for today’s most pressing recycling and regulatory challenges.

Interview

Strategic Response to a Shifting Pharma Landscape

Stability in Motion

Stefan Oelrich, Member of the Board of Management and President Pharmaceuticals, Bayer, discusses navigating external volatility, reshaping its internal structures, and investing in future-ready capabilities to ensure sustainable growth.